Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. IBM
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. TSLA

Go back to Alkermes (ALKS) Granted FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer

Alkermes (ALKS) Tops Q3 EPS by 8c

October 27, 2021 7:05 AM EDT

Alkermes (NASDAQ: ALKS) reported Q3 EPS of $0.14, $0.08 better than the analyst estimate of $0.06. Revenue for the quarter came in at $294.1 million versus the consensus estimate of $301.59 million.

For earnings history and earnings-related data on Alkermes (ALKS) click here.

... More

Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

October 26, 2021 7:12 AM EDT

Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-7, a global phase 3, open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin alfa (nemvaleukin), in combination with pembrolizumab, compared to investigator's choice chemotherapy, in patients with platinum-resistant ovarian cancer. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is a novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy. As... More

Increasing unusual call option volume: ALKS COMM DECK TWO SOL THC SGOC

October 21, 2021 9:58 AM EDT

Increasing unusual call option volume: ALKS COMM DECK TWO SOL THC SGOC

... More